PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
238.00 - 242.07
140.53 - 242.25
26.77M / 38.44M (Avg.)
25.64 | 9.39
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
7.17%
Revenue growth at 50-75% of META's 12.00%. Martin Whitman would worry about competitiveness or product relevance.
6.50%
Gross profit growth at 50-75% of META's 10.75%. Martin Whitman would question if cost structure or brand is lagging.
38.92%
EBIT growth above 1.5x META's 4.89%. David Dodd would confirm if core operations or niche positioning yield superior profitability.
38.92%
Operating income growth above 1.5x META's 4.89%. David Dodd would confirm if consistent cost or pricing advantages drive this outperformance.
49.42%
Net income growth above 1.5x META's 7.70%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
50.00%
EPS growth above 1.5x META's 8.24%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
47.92%
Diluted EPS growth above 1.5x META's 7.06%. David Dodd would see if there's a robust moat protecting these shareholder gains.
-0.11%
Share reduction while META is at 0.60%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.13%
Reduced diluted shares while META is at 0.21%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
5.22%
Positive OCF growth while META is negative. John Neff would see this as a clear operational advantage vs. the competitor.
-11.70%
Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.
541.81%
10Y revenue/share CAGR under 50% of META's 1511.89%. Michael Burry would suspect a lasting competitive disadvantage.
137.40%
5Y revenue/share CAGR under 50% of META's 425.85%. Michael Burry would suspect a significant competitive gap or product weakness.
78.99%
3Y revenue/share CAGR under 50% of META's 165.77%. Michael Burry might see a serious short-term decline in relevance vs. the competitor.
614.22%
10Y OCF/share CAGR under 50% of META's 5605.55%. Michael Burry would worry about a persistent underperformance in cash creation.
118.25%
Below 50% of META's 482.17%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
36.82%
3Y OCF/share CAGR under 50% of META's 172.88%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
509.68%
Net income/share CAGR at 50-75% of META's 831.23%. Martin Whitman might question if the firm’s product or cost base lags behind.
188.70%
5Y net income/share CAGR similar to META's 200.84%. Walter Schloss might see both on parallel mid-term trajectories.
101.55%
3Y net income/share CAGR above 1.5x META's 16.43%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
453.67%
Equity/share CAGR of 453.67% while META is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
95.22%
Below 50% of META's 338.44%. Michael Burry sees a substantially weaker mid-term book value expansion strategy in place.
48.52%
3Y equity/share CAGR at 50-75% of META's 78.46%. Martin Whitman sees a short-term lag in net worth creation vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
10.68%
AR growth well above META's 16.03%. Michael Burry fears inflated revenue or higher default risk in the near future.
-8.45%
Inventory is declining while META stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
4.79%
Asset growth at 50-75% of META's 6.88%. Martin Whitman questions if the firm is lagging expansions or if the competitor invests more aggressively.
4.87%
BV/share growth above 1.5x META's 1.99%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
7.25%
Debt growth far above META's 8.32%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
3.05%
R&D dropping or stable vs. META's 15.91%. David Dodd sees near-term margin benefits if the product pipeline is already strong.
4.37%
We expand SG&A while META cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.